Discovery services by Ncardia - Established cell models
Ncardia offers a range of human iPSC-derived cardiac and neural cell models that can be used in drug discovery.

Ncardia supplies human iPSC-derived cell models, screening assays and custom iPSC services to biopharmaceutical companies in drug discovery.
ncardia.comCrawled Nov 4, 2026
Ncardia offers a range of human iPSC-derived cardiac and neural cell models that can be used in drug discovery.
Ncardia offers phenotypically relevant human iPSC-derived in vitro models for drug discovery
Explore iPSC services that streamline candidate selection and enhance clinical translation.
Charles Jacques joined Ncardia and Cellistic as CFO to support growth in allogeneic immune cell therapy and drug discovery.
Insights by Ncardia - News
Ncardia forms strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and discovery services.
Neurizon’s NUZ-001 reduced TDP-43 aggregation and improved motor neuron function in preclinical ALS research.
Ncardia hires skilled professionals for open positions.
Ncardia offers iPSC-focused drug discovery services with a flexible team.
Meet Ncardia, the proven iPSC experts that empower more confident decisions and accelerate the development of breakthrough therapies.
Ncardia integrates iPSC expertise, assay capabilities, and human disease biology into early drug discovery.
Ncardia collaborates with clients to develop customized project solutions.
Ncardia provides certificates of analysis and user guides.
Feedback from this 3-minute survey will help Ncardia better help drug innovators develop new therapies faster.
Ncardia provides human iPSC CRO services and cell models for drug discovery, safety pharmacology and disease modelling.
Ncardia's privacy policy
Ncardia's terms and conditions.
NCARDA highlights risks in immuno-oncology (IO) biologics development, where late-stage preclinical toxicology issues can disrupt lead selection and clinical planning. Complex therapies like antibody-drug conjugates (ADCs), monoclonal antibodies, and T cell therapies require rigorous safety assessments to avoid delays. Safety liabilities often emerge after significant progress in development pipelines.
Jason Conner has been appointed CEO of Cellistic, a company specializing in allogeneic iPSC-derived cell therapy manufacturing and development. He will also lead Ncardia, a sister company focused on stem cell-based drug discovery and safety assessment. Conner joined the Board of Directors in 2022.
Pharmaceutical companies are prioritizing early safety assessments and human-relevant preclinical models to inform drug development strategies. The industry now emphasizes aligning model accuracy with human biology before committing significant resources. This shift reshapes how discovery and development programs are designed and funded.
Ncardia and Leiden University Medical Center (LUMC) have created an automated platform for generating human cardiac microtissues. This system enables high-throughput drug screening to accelerate early-stage cardiac drug discovery. The collaboration aims to enhance the speed, reliability, and clinical relevance of testing methods.
Leiden University Medical Center (LUMC) and Ncardia collaborate to create an automated system for producing 3D cardiac microtissues. The platform streamlines high-throughput drug testing for cardiac medications by enabling rapid, large-scale evaluations. Researchers can now assess drug effects on heart tissue more efficiently than before.
Ncardia secures **$60 million** in funding from investment platform **Kiniciti** to advance **iPSC-derived therapies**. The Belgian firm specializes in integrating **human-induced pluripotent stem cell (iPSC) technologies** into drug discovery, offering **cardiovascular, neural, and immune cell models** for biopharmaceutical pipelines.
Ncardia secures **$60 million** in funding through a strategic partnership with **Kiniciti** to scale its **human-induced pluripotent stem cell** discovery and commercial production services. The company leverages stem cell technologies to support drug discovery and regenerative medicine applications. This funding will likely accelerate expansion of its production capabilities and service offerings.